Member Matthew Gardella was a panelist on Scrip's M&A Podcast, where he discussed the state of biopharma M&A, including the record pace of activity in 2023 and the implications of mega deals like the Pfizer/Seagen merger.
SOURCE
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.